Cryoport reports first quarter 2024 financial results

Q1 2024 revenue of $54.6 million 9% year-over-year increase in commercial cell & gene therapy revenue 9% year-over-year increase in biostorage/bioservices revenue a total of 675 global clinical trials supported as of march 31, 2024 $242 - $252 million full year 2024 revenue guidance reiterated nashville, tenn. , may 7, 2024 /prnewswire/ -- cryoport, inc. (nasdaq: cyrx) (cryoport), a global leader in supply chain solutions for the life sciences, today announced financial results for the three months ended march 31 (q1), 2024.
CYRX Ratings Summary
CYRX Quant Ranking